Triple
T3746951
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | CAPTOR-M |
E81231
|
entity |
| Predicate | successor |
P78
|
FINISHED |
| Object | CAPTOR-E |
E81556
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: CAPTOR-E | Statement: [CAPTOR-M, successor, CAPTOR-E]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: CAPTOR-E Context triple: [CAPTOR-M, successor, CAPTOR-E]
-
A.
CAPTOR-E
chosen
CAPTOR-E is an advanced active electronically scanned array (AESA) radar variant developed for modern fighter aircraft, notably the Eurofighter Typhoon, offering improved detection, tracking, and electronic warfare capabilities.
-
B.
CAPTOR-M
CAPTOR-M is an advanced mechanically scanned multi-mode radar variant used primarily on Eurofighter Typhoon aircraft for air-to-air and air-to-ground operations.
-
C.
CLEOPATRA trial
The CLEOPATRA trial was a pivotal phase III clinical study that demonstrated improved survival by adding pertuzumab (Perjeta) to trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.
-
D.
CESAER
CESAER is a European association of leading universities of science and technology that collaborates to advance engineering education, research, and innovation.
-
E.
Qontigo
Qontigo is a financial technology and indexing company known for providing index, analytics, and risk management solutions to global investors.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69ad8b19b7b08190a6188804e99c53e9 |
completed | March 8, 2026, 2:43 p.m. |
| NER | Named-entity recognition | batch_69adcb69887c8190a3f1188ec85727b0 |
completed | March 8, 2026, 7:18 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69b4db2f5e9881908c10feafbb569f48 |
completed | March 14, 2026, 3:51 a.m. |
Created at: March 8, 2026, 3:35 p.m.